IsoTherapeutics is a radiopharmaceutical company founded in 2005 by two passionate scientists. With an extensive background in chelation and radiochemistry, the company specializes in the development of innovative pharmaceuticals. They have received over 100 patents for their advancements in chemistry and radiopharmaceutical formulations.

IsoTherapeutics is known for their groundbreaking radiopharmaceutical, QUADRAMET®, which provides effective treatment for bone pain caused by metastatic cancer, as well as other conditions such as arthritis, osteoporosis, and osteomyelitis. What sets IsoTherapeutics apart is their commitment to collaboration and innovation. They offer a wide range of services, including radiolabeling proteins and antibody conjugates for pre-clinical research, bio-distribution and pharmacokinetic studies, and analytical capabilities such as GC, ICP, and HPLC.

Through their close collaborations with universities, medical centers, and venture capitalist groups, IsoTherapeutics aims to develop novel diagnostic and therapeutic agents for severe diseases. With a state-of-the-art cGMP manufacturing facility and a dedicated team of scientists, IsoTherapeutics is at the forefront of advancing the science of radiopharmaceuticals. Contact them today to learn more about their cutting-edge solutions